Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR

TLDR

• Theriva Biologics (TOVX) stock jumped 63% after releasing new data from its VIRAGE Phase 2b trial
• VCN-01 plus standard chemotherapy showed improved overall survival vs chemo alone in metastatic pancreatic cancer
• Benefits held across subgroups, including patients with liver metastases
• Theriva has FDA and EMA alignment on a planned Phase 3 pivotal trial
• The company has a market cap of just $11.7M and trades at $0.25, reflecting its clinical-stage risk

Theriva Biologics presented new data from its VIRAGE Phase 2b trial at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 20, 2026.

Theriva Biologics, Inc., TOVX

The poster session was led by Dr. Manuel Hidalgo of NYU Langone Health’s Perlmutter Cancer Center.

The trial tested VCN-01 combined with gemcitabine and nab-paclitaxel against chemotherapy alone in patients with newly diagnosed metastatic pancreatic cancer.

Results showed that patients receiving VCN-01 plus chemotherapy had better overall survival and progression-free survival than those on chemotherapy alone.

The responses in the VCN-01 group were described as later-emerging, higher in magnitude, and more durable — pointing to what the company believes is an immune-mediated mechanism of action.

The survival benefit was generally consistent across patient subgroups. That includes patients with liver metastases, who are typically harder to treat.

Patients who received a second dose of VCN-01 appeared to show even greater benefit, which the company says reinforces the case for extended dosing.

FDA and EMA Alignment on Phase 3

Theriva said it has reached alignment with both the FDA and the European Medicines Agency on the design of a pivotal Phase 3 trial.

The proposed Phase 3 would evaluate multiple doses of VCN-01 alongside gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer patients.

The company also said it plans a smaller study to explore whether more frequent or extended VCN-01 dosing could push outcomes further.

VCN-01 is a systemically administered oncolytic adenovirus. It is designed to replicate inside tumor cells and break down tumor stroma, potentially improving access for co-administered therapies.

To date, the treatment has been given to 142 patients across clinical trials covering several cancer types.

Stock Reaction and Company Profile

TOVX stock jumped 63% on the news, though the company’s market cap remains just $11.7 million at a stock price of $0.25.

That valuation reflects the risks attached to a clinical-stage biotech with no revenue and ongoing cash burn.

Analyst View

The most recent analyst rating on TOVX is a Buy, with a price target of $1.00. Price targets across analysts range from $1 to $4.

One complicating factor: Theriva was unable to hold a Special Meeting of Stockholders recently due to a lack of quorum. The meeting was meant to approve a warrant exercise proposal. The company plans to reschedule.

Pancreatic ductal adenocarcinoma makes up more than 90% of all pancreatic tumors, with 50–60% of patients already having distant metastases at diagnosis.

The AACR presentation took place April 20 from 2:00–5:00 PM PDT at the San Diego Convention Center.

The post Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR appeared first on CoinCentral.